Cultech Ltd,   Report issue

For profit Phase 2
Founded: Port Talbot United Kingdom (1994)
Status: No NME R&D (1994)

Organization Overview

First Clinical Trial
2015
NCT02373995
First Marketed Drug
None
First NDA Approval
None
Last Known Activity
2023

Timeline

NOW
  • Now

Alternative names

Cultech Ltd

Active Ingredients

Drugs in Phase 2 Trials (1)

bifidobacterium animalis (1 trial)

Drugs in Other Trials (4)

bifidobacteria (1 trial)

bifidobacterium bifidum (1 trial)

lactobacillus (1 trial)

saccharomyces boulardii (1 trial)

Indications

Experimental Indications (Clinical Trials, Phases 1-4)


 

Graves Disease (Phase 2)

Graves Ophthalmopathy (Phase 2)

Overview

  • Highest Phase: Phase 2
  • # of Trials: 3
  • # of Trial APIs: 5